Endothelial recovery: the next target in restenosis prevention.

By most accounts, the field of interventional cardiology appears to have achieved one of its most elusive milestones, the virtual eradication of restenosis. In the present issue of Circulation, however, Hedman and colleagues 1 report the results of a pilot study of gene therapy with vascular endothelial growth factor (VEGF) for restenosis prevention. Are these authors attempting to develop a treatment for a disease that no longer exists? Or is it possible that the mounting exuberance anticipating the release of drug-eluting stents is ignoring a major liability of these otherwise promising therapies? See p 2677

[1]  Y. Yoon,et al.  Local Gene Transfer of phVEGF-2 Plasmid by Gene-Eluting Stents: An Alternative Strategy for Inhibition of Restenosis , 2004, Circulation.

[2]  J. Hartikainen,et al.  Safety and Feasibility of Catheter-Based Local Intracoronary Vascular Endothelial Growth Factor Gene Transfer in the Prevention of Postangioplasty and In-Stent Restenosis and in the Treatment of Chronic Myocardial Ischemia: Phase II Results of the Kuopio Angiogenesis Trial (KAT) , 2003, Circulation.

[3]  Douglas Losordo,et al.  Biological revascularization and the interventional molecular cardiologist: bypass for the next generation. , 2002, Circulation.

[4]  F. Welt,et al.  Inflammation and Restenosis in the Stent Era , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[5]  R. Virmani,et al.  Sustained Reduction of In-Stent Neointimal Growth With the Use of a Novel Systemic Nanoparticle Paclitaxel , 2002, Circulation.

[6]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[7]  C. Di Mario,et al.  First Clinical Experience With a Paclitaxel Derivate–Eluting Polymer Stent System Implantation for In-Stent Restenosis: Immediate and Long-Term Clinical and Angiographic Outcome , 2002, Circulation.

[8]  P. Teirstein,et al.  Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. , 2002, The New England journal of medicine.

[9]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[10]  A. Colombo,et al.  Late acute thrombosis after paclitaxel eluting stent implantation , 2001, Heart.

[11]  R. Virmani,et al.  Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent , 2001, Circulation.

[12]  M. Sata,et al.  Fas Ligand Overexpression on Allograft Endothelium Inhibits Inflammatory Cell Infiltration and Transplant-Associated Intimal Hyperplasia1 , 2001, The Journal of Immunology.

[13]  J. Isner,et al.  Vascular endothelial growth factor-induced angiogenesis: crouching tiger or hidden dragon? , 2001, Journal of the American College of Cardiology.

[14]  R. Virmani,et al.  Late Arterial Responses (6 and 12 Months) After 32P &bgr;-Emitting Stent Placement: Sustained Intimal Suppression With Incomplete Healing , 2001, Circulation.

[15]  M. Dake,et al.  Vascular endothelial growth factor enhances atherosclerotic plaque progression , 2001, Nature Medicine.

[16]  J. Willerson,et al.  Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. Teirstein,et al.  Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. , 2001, The New England journal of medicine.

[18]  M. Leon,et al.  Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. , 2000, Journal of the American College of Cardiology.

[19]  R A Schatz,et al.  Three-year clinical and angiographic follow-up after intracoronary radiation : results of a randomized clinical trial. , 2000, Circulation.

[20]  M A Konerding,et al.  Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.

[21]  E. Edelman,et al.  A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Isner,et al.  Reciprocal relation between VEGF and NO in the regulation of endothelial integrity , 1997, Nature Medicine.

[23]  J. Isner,et al.  Histopathology of in-stent restenosis in patients with peripheral artery disease. , 1997, Circulation.

[24]  J. Isner,et al.  Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. , 1997, Circulation.

[25]  J. Isner,et al.  Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. , 1996, Circulation.

[26]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[27]  J. Isner.  Vascular remodeling. Honey, I think I shrunk the artery. , 1994, Circulation.

[28]  R. Ross,et al.  Rous-Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry. , 1993, The American journal of pathology.

[29]  L. Williams,et al.  Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[31]  S. Ellis,et al.  Clinical success, complications and restenosis rates with excimer laser coronary angioplasty. The Percutaneous Excimer Laser Coronary Angioplasty Registry. , 1992, The American journal of cardiology.

[32]  G. Roubin,et al.  Histopathologic phenomena at the site of percutaneous transluminal coronary angioplasty: the problem of restenosis. , 1989, Human pathology.

[33]  J. Pepper,et al.  Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. , 1988, British heart journal.

[34]  W. Baker,et al.  Pathologic characteristics of recurrent carotid artery stenosis. , 1987, Journal of vascular surgery.

[35]  V. Fuster,et al.  Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. , 1985, Circulation research.

[36]  J. Palmaz,et al.  Postoperative carotid restenosis due to neointimal fibromuscular hyperplasia. Clinical, angiographic, and pathological findings. , 1983, Radiology.

[37]  P. Vanhoutte,et al.  The endothelium as a regulator of vascular smooth muscle proliferation , 1993 .